Trevi Therapeutics Stock Forecast, Price & News

Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions

Is Trevi Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Trevi Therapeutics stock.
View analyst ratings for Trevi Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Trevi Therapeutics?

Wall Street analysts have given Trevi Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trevi Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Trevi Therapeutics?

Trevi Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totaling 139,700 shares, an increase of 25.9% from the September 30th total of 111,000 shares. Based on an average daily trading volume, of 373,200 shares, the short-interest ratio is currently 0.4 days. Currently, 2.4% of the shares of the company are sold short.
View Trevi Therapeutics' Short Interest.

When is Trevi Therapeutics' next earnings date?

Trevi Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Trevi Therapeutics.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) posted its quarterly earnings data on Thursday, August, 12th. The company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.03.
View Trevi Therapeutics' earnings history.

How has Trevi Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Trevi Therapeutics' stock was trading at $3.18 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TRVI shares have decreased by 64.8% and is now trading at $1.12.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TRVI?

1 equities research analysts have issued 12 month price objectives for Trevi Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Trevi Therapeutics' share price to reach $10.00 in the next year. This suggests a possible upside of 792.9% from the stock's current price.
View analysts' price targets for Trevi Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Trevi Therapeutics' key executives?

Trevi Therapeutics' management team includes the following people:

• Jennifer L. Good, President, Chief Executive Officer & Director
• Lisa Delfini, Chief Financial Officer
• Thomas R. Sciascia, Chief Medical Officer
• Danine Summers, Vice President-Medical Affairs
• William P. Forbes, Chief Development Officer

Who are some of Trevi Therapeutics' key competitors?

Some companies that are related to Trevi Therapeutics include Evofem Biosciences (EVFM), Daré Bioscience (DARE), AcelRx Pharmaceuticals (ACRX), Edesa Biotech (EDSA), Catalyst Biosciences (CBIO), Processa Pharmaceuticals (PCSA), Aprea Therapeutics (APRE), Eyenovia (EYEN), Xynomic Pharmaceuticals (XYNO), Ainos (AIMD), Iterum Therapeutics (ITRM), Opiant Pharmaceuticals (OPNT), Exicure (XCUR), Jaguar Health (JAGX) and Longboard Pharmaceuticals (LBPH).
View all of TRVI's competitors.

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX).

When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an IPO on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

How do I buy shares of Trevi Therapeutics?

Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $1.12.

How much money does Trevi Therapeutics make?

Trevi Therapeutics has a market capitalization of $26.88 million. The company earns $-32.76 million in net income (profit) each year or ($1.81) on an earnings per share basis.

How many employees does Trevi Therapeutics have?

Trevi Therapeutics employs 8 workers across the globe.

What is Trevi Therapeutics' official website?

The official website for Trevi Therapeutics is www.trevitherapeutics.com.

Where are Trevi Therapeutics' headquarters?

Trevi Therapeutics is headquartered at 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at (203) 304-2499 or via email at [email protected].